Skip to main content
Premium Trial:

Request an Annual Quote

Foundation Medicine Collaborating with Array BioPharma on Cancer Biomarkers

Premium

Foundation Medicine said this week that it is working with Array BioPharma to help identify cancer patients who will respond to targeted therapy with Array's cancer agents.

Under the collaboration, Foundation Medicine will use its DNA sequencing and analysis capabilities to determine the genetic profile of tumors from patients who are treated with Array's drugs.

Array BioPharma has a number of targeted cancer agents in early stages of clinical development. The goal of the partnership is to be able to identify patients who may respond to treatment with a specific drug.

Foundation Medicine already has a number of other partnerships with pharmaceutical companies, including Sanofi, Johnson & Johnson, Novartis, and Celgene.

The company plans to launch its targeted sequencing-based cancer diagnostic test to identify clinically actionable mutations in June (CSN 2/22/2012).

The Scan

Vaccine Update Recommended

A US Food and Drug Administration panel recommends booster vaccines be updated to target Omicron, CNBC reports.

US to Make More Vaccines for Monkeypox Available

The US is to make nearly 300,000 vaccine doses available in the coming weeks to stem the spread of human monkeypox virus, according to NPR.

Sentence Appealed

The Associated Press reports that Swedish prosecutors are appealing the sentence given to a surgeon once lauded for transplanting synthetic tracheas but then convicted of causing bodily harm.

Genome Biology Papers on COVID-19 Effector Genes, Virtual ChIP-seq, scDART

In Genome Biology this week: proposed COVID-19 effector genes, method to predict transcription factor binding patterns, and more.